The rise of Sildenafil initially sparked a surge for major pharmaceutical companies, nevertheless recent shifts present a uncertain outlook for those considering a stake. Generic alternatives are eating into profits, and ongoing litigation add additional difficulty to the landscape. While certain companies could still see gains from adjacent offeri